drugset / Trial / NCT02388581
First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL
Phase 2
Unknown
30 enrolled
National Health Research Institutes, Taiwan
Chang Gung Memorial Hospital · collabChanghua Christian Hospital · collabChina Medical University Hospital · collabKaohsiung Medical University · collabMackay Memorial Hospital · collabNational Cheng-Kung University Hospital · collabNational Taiwan University Hospital · collabTaichung Veterans General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Aims: A nationwide study to prospectively validate 1. The complete histological and molecular remission rate for antibiotics as 1st-line therapy for early-stage Hp-positive gastric pure (de novo) DLBCL 2. The durability of complete histological remission after antibiotics 3. The usefulness of pattern of NF-kB, BCL10, BAFF, and CagA by IHC staining in prospectively predicting the Hp-dependence of gastric pure (de novo) DLBCL 4. The frequency of t(11;18)(q21;q21) translocation in gastric pure (de novo) DLBCL in Taiwan. 5. The association between the CYP2C18/CYP2C19 genetic polymorphisms and eradication of Hp infection after antibiotics.
Timeline
- Start
- 2014-12
- Primary completion
- 2017-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | — | — |
| Subject | Clarithromycin | Small molecule | — | — |
| Subject | Lansoprazole | Other / unclassified | — | — |
| Subject | Metronidazole | Small molecule | — | — |